Crispr Therapeutics Ag - Common Shares (CRSP) closed at $45.75 on November 11, 2026, up 1.3% from the previous close, on volume of 2,622,121 shares (30-day average 1,467,256).
Data as of November 11, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 16, 2026 | Diagonal Put Spread | 16-Oct : 20-Nov-2655 : 52.5 P | 2,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
TipRanks (Tue, 10-Nov 9:01 AM ET)
CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
Globe Newswire (Tue, 10-Nov 8:30 AM ET)
Needham Remains a Buy on Crispr Therapeutics AG (CRSP)
TipRanks (Mon, 9-Nov 11:15 AM ET)
Globe Newswire (Mon, 9-Nov 9:16 AM ET)
J.P. Morgan Keeps Their Buy Rating on Crispr Therapeutics AG (CRSP)
TipRanks (Mon, 9-Nov 8:16 AM ET)
TipRanks (Mon, 9-Nov 8:10 AM ET)
CRISPR Therapeutics: Encouraging zugo-cel Data Support Buy; $80 Price Target Reiterated
TipRanks (Mon, 9-Nov 7:35 AM ET)
TipRanks (Mon, 9-Nov 6:15 AM ET)
Globe Newswire (Sun, 8-Nov 10:30 AM ET)
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Crispr Therapeutics Ag - Common Shares trades on the NASDAQ stock market under the symbol CRSP.
As of November 11, 2026, CRSP stock price climbed to $45.75 with 2,622,121 million shares trading.
CRSP has a beta of 1.96, meaning it tends to be more sensitive to market movements. CRSP has a correlation of 0.20 to the broad based SPY ETF.
CRSP has a market cap of $4.42 billion. This is considered a Mid Cap stock.
Last quarter Crispr Therapeutics Ag - Common Shares reported $13 million in Revenue and -$1.15 earnings per share. This fell short of revenue expectation by $-3 million and missed earnings estimates by -$.09.
In the last 3 years, CRSP traded as high as $91.10 and as low as $30.04.
The top ETF exchange traded funds that CRSP belongs to (by Net Assets): ARKE, ARKK, XBI, IWM, ARKG.
CRSP has underperformed the market in the last year with a price return of -16.2% while the SPY ETF gained +12.6%. CRSP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -14.5% and -11.1%, respectively, while the SPY returned -1.5% and -1.3%, respectively.
CRSP support price is $43.45 and resistance is $46.85 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRSP shares will trade within this expected range on the day.
